JP2015506955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506955A5 JP2015506955A5 JP2014555195A JP2014555195A JP2015506955A5 JP 2015506955 A5 JP2015506955 A5 JP 2015506955A5 JP 2014555195 A JP2014555195 A JP 2014555195A JP 2014555195 A JP2014555195 A JP 2014555195A JP 2015506955 A5 JP2015506955 A5 JP 2015506955A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patient
- composition according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940125497 HER2 kinase inhibitor Drugs 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 14
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 14
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 10
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 10
- 229960000575 trastuzumab Drugs 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 6
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 6
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229960004891 lapatinib Drugs 0.000 claims description 4
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 229940121647 egfr inhibitor Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 238000000034 method Methods 0.000 description 30
- 239000003550 marker Substances 0.000 description 1
- 208000013066 thyroid gland cancer Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592893P | 2012-01-31 | 2012-01-31 | |
| US61/592,893 | 2012-01-31 | ||
| US201261654733P | 2012-06-01 | 2012-06-01 | |
| US61/654,733 | 2012-06-01 | ||
| PCT/EP2013/051865 WO2013113796A1 (en) | 2012-01-31 | 2013-01-31 | Method of treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506955A JP2015506955A (ja) | 2015-03-05 |
| JP2015506955A5 true JP2015506955A5 (enExample) | 2016-03-24 |
Family
ID=47714037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014555195A Pending JP2015506955A (ja) | 2012-01-31 | 2013-01-31 | がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150023953A1 (enExample) |
| EP (2) | EP2809805A1 (enExample) |
| JP (1) | JP2015506955A (enExample) |
| KR (1) | KR20140117644A (enExample) |
| CN (1) | CN104204226A (enExample) |
| AU (1) | AU2013214254B2 (enExample) |
| BR (1) | BR112014019034A8 (enExample) |
| CA (1) | CA2863287A1 (enExample) |
| IN (1) | IN2014DN06127A (enExample) |
| RU (1) | RU2014135224A (enExample) |
| WO (1) | WO2013113796A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109504743A (zh) * | 2017-09-13 | 2019-03-22 | 复旦大学附属华山医院 | 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒 |
| CA3166298A1 (en) * | 2020-01-29 | 2021-08-05 | John Heymach | Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| WO1997040462A2 (en) | 1996-04-19 | 1997-10-30 | Spectra Biomedical, Inc. | Correlating polymorphic forms with multiple phenotypes |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| AU7307101A (en) | 2000-06-30 | 2002-01-14 | Glaxo Group Ltd | Quinazoline ditosylate salt compounds |
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| US20100104583A1 (en) * | 2007-01-18 | 2010-04-29 | University Of Southern California | Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy |
| EP2126117A2 (en) * | 2007-01-18 | 2009-12-02 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
| EP1980626A1 (en) * | 2007-04-13 | 2008-10-15 | Het Nederlands Kanker Instituut | Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy |
| WO2008128233A1 (en) * | 2007-04-15 | 2008-10-23 | University Of Chicago | Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr) |
| SG178439A1 (en) * | 2009-08-21 | 2012-04-27 | Smithkline Beecham Cork Ltd | Method of treating cancer |
| WO2011060380A1 (en) * | 2009-11-14 | 2011-05-19 | The Regents Of The University Of California | Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer |
-
2013
- 2013-01-31 AU AU2013214254A patent/AU2013214254B2/en not_active Ceased
- 2013-01-31 RU RU2014135224A patent/RU2014135224A/ru not_active Application Discontinuation
- 2013-01-31 JP JP2014555195A patent/JP2015506955A/ja active Pending
- 2013-01-31 EP EP13704029.1A patent/EP2809805A1/en not_active Withdrawn
- 2013-01-31 US US14/375,969 patent/US20150023953A1/en not_active Abandoned
- 2013-01-31 KR KR1020147023977A patent/KR20140117644A/ko not_active Withdrawn
- 2013-01-31 CN CN201380017091.3A patent/CN104204226A/zh active Pending
- 2013-01-31 WO PCT/EP2013/051865 patent/WO2013113796A1/en not_active Ceased
- 2013-01-31 EP EP15196262.8A patent/EP3045543A3/en not_active Withdrawn
- 2013-01-31 CA CA2863287A patent/CA2863287A1/en not_active Abandoned
- 2013-01-31 BR BR112014019034A patent/BR112014019034A8/pt not_active IP Right Cessation
-
2014
- 2014-07-21 IN IN6127DEN2014 patent/IN2014DN06127A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Minniti et al. | Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents | |
| JP7367910B2 (ja) | がんの処置 | |
| US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
| Camidge et al. | A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non–small-cell lung cancer | |
| Perez et al. | Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation | |
| US20140135370A1 (en) | Treating cancer with an hsp90 inhibitory compound | |
| Mukhopadhyay et al. | RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib | |
| JP2014533284A5 (enExample) | ||
| JP2014097929A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2014530215A5 (enExample) | ||
| JP2017511377A5 (enExample) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| JP2019511550A5 (enExample) | ||
| Renouf et al. | A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer | |
| MX2013015333A (es) | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos. | |
| WO2023230222A1 (en) | Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor | |
| Gounant et al. | Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer | |
| JP2015506955A5 (enExample) | ||
| CA2944255C (en) | New derivatives of cephalosporin for treating cancer | |
| RU2015154985A (ru) | Способы лечения рака | |
| AU2021397214B2 (en) | Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors | |
| ES3032036T3 (en) | Methods and compositions comprising a krasg12c inhibitor and a vegf inhibitor for treating solid tumors | |
| RU2014123166A (ru) | Восприимчивость к ингибиторам ангиогенеза | |
| Sohn | Next generation sequencing and anti-cancer therapy |